For decades, one of the world’s most contagious diseases was considered eradicated in the U.S. But now measles is roaring ...

Professor Hirohide Saito and his research team have developed a new microRNA-responsive hybrid mRNA switch, enabling precise, ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

Many Indian firms chase quick returns, rely on imported technology, and underinvest in research. But innovation needs ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The government’s top vaccine official, working under Health Secretary Robert F. Kennedy Jr., restricted the approval of two ...

The US Advisory Committee on Immunization Practices voted in June to stop recommending certain kinds of flu vaccines, a ...